TIME-OUT-GROUP-PLC
7.10.2021 01:03:11 CEST | Business Wire | Press release
Time Out has revealed that Nørrebro in Copenhagen tops its fourth annual World’s Coolest Neighbourhoods list: the cultural and culinary hotspots that are leading the way as we begin to emerge from the pandemic.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211006005865/en/
Since 2018, Time Out’s World’s Coolest Neighbourhoods list has been collated using responses from the Time Out Index survey, combined with the expertise of Time Out’s international network of local editors and city experts. This year, more than 27,000 global city-dwellers nominated their city’s coolest, most underrated and most culturally exciting neighbourhood. To create and rank the final list, Time Out’s local expert editors and writers rated neighbourhoods for great vibes, food, drink, nightlife, emerging culture, community spirit and resilience. They also considered sustainability, innovative green initiatives and other factors that promote stress-free living.
Nørrebro is a diverse district where history meets ultramodern architecture on the northern side of Copenhagen’s lakes, and it truly has it all. In a city proudly known for its food and drink scene, Nørrebro has seen a flurry of new openings this year from bakeries to natural wine bars, all with a focus on local, seasonal (and often foraged) produce. The neighbourhood was host to the city’s Pride march this summer, when WorldPride came to Copenhagen – the most significant LGBTQ+ event in the world. In a year where community has been more important than ever, Nørrebro has no shortage of innovative initiatives including Nørrebrogade’s Car-Free Sunday where traffic is swapped for live music and flea markets, and Usynglige Stier (‘Invisible Paths’) an interactive art exhibition that brings fun and a splash of colour to the neighbourhood’s most vulnerable areas.
Caroline McGinn, Time Out’s Global Editor-in-Chief, said: “Time Out’s annual list of the World’s Coolest Neighbourhoods is a love letter to the city at its most joyful and surprising. It celebrates the hyperlocal places where cities of the future are being made up, on the spot. In the last year, grassroots community culture has been vital to preserving the health and optimism of city-dwellers and the restaurants, bars, galleries and culture spots that make cities such a crucible of invention and social life. It’s inspiring to see how much energy there is in these areas, where communities have come together, hung out and made new stuff, as well as supported other businesses and each other. You’ve probably never heard of most of the neighbourhoods on the list but these are places where a ‘better normal’ is emerging. I can’t wait to visit.”
Read the full list at www.timeout.com/coolest-neighbourhoods-in-the-world
1. Nørrebro, Copenhagen
2. Andersonville, Chicago
3. Jongno 3-ga, Seoul
4. Leith, Edinburgh
5. Station District, Vilnius
6. Chelsea, New York
7. XI District, Budapest
8. Ngor, Dakar
9. Sai Kung, Hong Kong
10. Richmond, Melbourne
11. Neukölln, Berlin
12. Centro, Medellín
13. Dalston, London
14. Silver Lake, Los Angeles
15. Dublin 8, Dublin
16. Zoloti Vorota, Kiev
17. Noord, Amsterdam
18. Villeray, Montreal
19. Surry Hills, Sydney
20. Ancoats, Manchester
21. Sagene, Oslo
22. Old Xuhui, Shanghai
23. Centro, Mexico City
24. Gràcia, Barcelona
25. Saúde, Rio de Janeiro
26. Kemptown, Brighton
27. Sololaki, Tbilisi
28. Brickell, Miami
29. Ouseburn, Newcastle
30. Barranco, Lima
31. Chamberí, Madrid
32. Vinohrady, Prague
33. Katong, Singapore
34. Anjos, Lisbon
35. Daikanyama, Tokyo
36. Haut-Marais, Paris
37. Al Bateen, Abu Dhabi
38. Foz, Porto
39. Central Square, Boston
40. Mount Pleasant, Vancouver
41. Jamestown, Accra
42. Centro, Oaxaca
43. Mouassine, Marrakech
44. Dubai Marina, Dubai
45. Kadikoy, Istanbul
46. Poblacion, Manila
47. Ari, Bangkok
48. Koregaon Park, Pune
49. El Arrayán, Santiago
View source version on businesswire.com: https://www.businesswire.com/news/home/20211006005865/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom